BTIG analyst Ryan Zimmerman raised his price target on NuVasive (NUVA) to $72 and kept his Buy rating following investor meetings with the management, saying the tone of the discussions was “decidedly more upbeat” after Q2 results and the company’s FY18 guidance cut. The analyst states that he also “underappreciated” the potential for NuVasive’s recent agreement with Siemens (SIEGY), as it expands the company’s opportunity and provides better commercial support. Zimmerman expects investor interest in NuVasive shares to build heading into the full launch of the company’s new Pulse system.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.